• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项针对美国泌尿科住院医师培训项目中使用 Xiaflex 治疗 Peyronie 病的暴露情况的调查。

A survey of exposure to the use of Xiaflex for the treatment of Peyronie's disease among United States urology residency programs.

机构信息

Department of Urology, Montefiore Medical Center, Bronx, NY, USA.

Washington State University Elson S. Floyd College of Medicine, Spokane, WA, USA.

出版信息

Int J Impot Res. 2024 Apr;36(2):155-159. doi: 10.1038/s41443-023-00781-7. Epub 2023 Oct 21.

DOI:10.1038/s41443-023-00781-7
PMID:37865716
Abstract

Xiaflex® (collagenase clostridium histolyticum) is a Food and Drug Administration-approved treatment for patients with Peyronie's disease. Despite its approval and implementation, there is concern that urologists in training are offered minimal exposure to its use. Thus, the purpose of this study was to evaluate the exposure of urology residents to Peyronie's disease and its management, particularly Xiaflex®. A Google Forms survey regarding the exposure of residents to Peyronie's disease and use of Xiaflex® was created and disseminated through email to urology programs. Overall, 47 institutional responses were received. At 45 institutions (95.7%), residents receive training in directly evaluating and caring for patients with Peyronie's disease. At 46 institutions (97.9%), residents receive training in observing and/or performing surgical procedures for Peyronie's disease. Residents at 31 institutions (66.0%) receive observational or procedural training for non-surgical management of Peyronie's disease, specifically Xiaflex®. Residents receive non-surgical training from an academic faculty who is fellowship trained in sexual medicine at 25 institutions and an academic faculty not trained in sexual medicine at six institutions. There exists a glaring disparity in residency exposure to Xiaflex®. Further research is warranted to elucidate how programs can provide residents with further exposure to the use of Xiaflex® in patients with Peyronie's disease.

摘要

Xiaflex®(胶原酶梭菌组织溶菌素)是一种经食品和药物管理局批准的治疗阴茎硬结症的药物。尽管已获得批准并付诸实施,但人们仍担心接受培训的泌尿科医生对其使用的接触非常有限。因此,本研究旨在评估泌尿科住院医师对阴茎硬结症及其管理(尤其是 Xiaflex®)的接触情况。我们创建了一个关于住院医师接触阴茎硬结症和使用 Xiaflex®的 Google 表单调查,并通过电子邮件分发给泌尿科项目。总共收到了 47 个机构的回复。在 45 个机构(95.7%)中,住院医师接受过直接评估和护理阴茎硬结症患者的培训。在 46 个机构(97.9%)中,住院医师接受过观察和/或进行阴茎硬结症手术程序的培训。在 31 个机构(66.0%)中,住院医师接受过阴茎硬结症非手术治疗的观察性或程序性培训,特别是 Xiaflex®。在 25 个机构中,住院医师接受了性医学专科培训的学术教员的非手术培训,在 6 个机构中,住院医师接受了未接受性医学专科培训的学术教员的非手术培训。住院医师接触 Xiaflex®的情况存在明显差异。需要进一步研究阐明计划如何为住院医师提供更多接触 Xiaflex®治疗阴茎硬结症患者的机会。

相似文献

1
A survey of exposure to the use of Xiaflex for the treatment of Peyronie's disease among United States urology residency programs.一项针对美国泌尿科住院医师培训项目中使用 Xiaflex 治疗 Peyronie 病的暴露情况的调查。
Int J Impot Res. 2024 Apr;36(2):155-159. doi: 10.1038/s41443-023-00781-7. Epub 2023 Oct 21.
2
Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol.采用新的改良缩短方案时,溶组织梭状芽孢杆菌胶原酶治疗佩罗尼氏病的安全性和有效性。
BJU Int. 2017 Nov;120(5):717-723. doi: 10.1111/bju.13932. Epub 2017 Jul 14.
3
[Collagenase clostridium histolyticum for Peyronie's disease: A new minimally invasive and effective treatment].溶组织梭状芽孢杆菌胶原酶治疗佩罗尼氏病:一种新的微创有效治疗方法
Zhonghua Nan Ke Xue. 2017 Sep;23(9):771-775.
4
Intralesional Collagenase Clostridium histolyticum Causes Meaningful Improvement in Men with Peyronie's Disease: Results of a Multi-Institutional Analysis.腔内胶原酶组织溶解疗法治疗男性阴茎硬结症:多中心分析结果。
J Urol. 2019 Apr;201(4):777-782. doi: 10.1097/JU.0000000000000032.
5
Lateral herniation during treatment with collagenase Clostridium histolyticum (Xiaflex) for Peyronie's disease.在使用胶原酶(希拉飞®,Xiaflex)治疗阴茎硬结症时发生的外侧疝。
BMC Urol. 2021 Jun 27;21(1):94. doi: 10.1186/s12894-021-00858-9.
6
Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study.溶组织梭状芽孢杆菌胶原酶注射治疗佩罗尼氏病患者的临床安全性和有效性:一项3期开放标签研究。
J Sex Med. 2015 Jan;12(1):248-58. doi: 10.1111/jsm.12731. Epub 2014 Nov 12.
7
Sildenafil 25 mg ODT + Collagenase Clostridium hystoliticum vs Collagenase Clostridium hystoliticum Alone for the Management of Peyronie's Disease: A Matched-Pair Comparison Analysis.西地那非 25 毫克口腔崩解片+胶原酶梭菌组织溶解酶与单独使用胶原酶梭菌组织溶解酶治疗阴茎硬结症的比较:配对比较分析。
J Sex Med. 2018 Oct;15(10):1472-1477. doi: 10.1016/j.jsxm.2018.08.012. Epub 2018 Sep 20.
8
Xiaflex for Treatment of Peyronie's Disease.夏法丝(Xiaflex)治疗阴茎硬结症。
Eur Urol Focus. 2018 Apr;4(3):302-303. doi: 10.1016/j.euf.2018.08.021. Epub 2018 Sep 10.
9
Collagenase Clostridium Histolyticum: A Review in Peyronie's Disease.胶原酶溶组织梭菌:对阴茎硬结症的评价。
Drugs. 2015 Aug;75(12):1405-12. doi: 10.1007/s40265-015-0441-7.
10
Collagenase clostridium histolyticum: a novel medical treatment for Peyronie's disease.溶组织梭状芽孢杆菌胶原酶:佩罗尼氏病的一种新型医学疗法。
Minerva Urol Nefrol. 2018 Aug;70(4):380-385. doi: 10.23736/S0393-2249.18.03118-1. Epub 2018 May 14.

本文引用的文献

1
Trends in treatment of Peyronie's disease in adult men in the United States from 2008 to 2017-results from an encounter and claims database.2008 年至 2017 年美国成年男性中 Peyronie 病治疗趋势——基于一次相遇和索赔数据库的研究。
Int J Impot Res. 2022 Apr;34(3):280-288. doi: 10.1038/s41443-021-00430-x. Epub 2021 Apr 7.
2
Treatment Patterns and Healthcare Outcomes with Collagenase Clostridium Histolyticum vs Surgery in Peyronie's Disease: A Retrospective Claims Database Analysis.胶原酶溶组织梭状芽孢杆菌与手术治疗佩罗尼氏病的治疗模式及医疗结局:一项回顾性索赔数据库分析
Sex Med. 2021 Apr;9(2):100321. doi: 10.1016/j.esxm.2021.100321. Epub 2021 Mar 5.
3
Survey of Microsurgery Training Availability in US Urology Residency Programs.
美国泌尿外科住院医师培训项目显微外科培训可用性调查。
World J Mens Health. 2021 Apr;39(2):376-380. doi: 10.5534/wjmh.190162. Epub 2020 May 18.
4
Prevalence of penile curvature: a population-based cross-sectional study in metropolitan and rural cities in Australia.阴茎弯曲患病率:澳大利亚城乡基于人群的横断面研究。
BJU Int. 2018 Nov;122 Suppl 5:42-49. doi: 10.1111/bju.14605.
5
Prevalence, psychological impact, and risk factors of erectile dysfunction in patients with Peyronie's disease: a retrospective analysis of 309 cases.佩罗尼氏病患者勃起功能障碍的患病率、心理影响及危险因素:309例回顾性分析
Res Rep Urol. 2016 Jul 18;8:95-103. doi: 10.2147/RRU.S109319. eCollection 2016.
6
The Prevalence of Peyronie's Disease in the United States: A Population-Based Study.美国佩罗尼氏病的患病率:一项基于人群的研究。
PLoS One. 2016 Feb 23;11(2):e0150157. doi: 10.1371/journal.pone.0150157. eCollection 2016.
7
An Analysis of Case Logs From American Urologists in the Treatment of Peyronie's Disease.美国泌尿科医生治疗佩罗尼氏病病例记录分析
Urology. 2016 Jan;87:205-9. doi: 10.1016/j.urology.2015.08.033. Epub 2015 Oct 19.
8
Peyronie's Disease: AUA Guideline.佩罗尼氏病:美国泌尿外科学会指南。
J Urol. 2015 Sep;194(3):745-53. doi: 10.1016/j.juro.2015.05.098. Epub 2015 Jun 9.
9
Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies.在 2 项大型、双盲、随机、安慰剂对照的 3 期研究中评估胶原酶注射治疗 Peyronie 病的临床疗效、安全性和耐受性。
J Urol. 2013 Jul;190(1):199-207. doi: 10.1016/j.juro.2013.01.087. Epub 2013 Jan 31.
10
Risk factors for emotional and relationship problems in Peyronie's disease.佩罗尼氏病中情绪和人际关系问题的风险因素。
J Sex Med. 2008 Sep;5(9):2179-84. doi: 10.1111/j.1743-6109.2008.00949.x. Epub 2008 Jul 14.